

1

2 **Comparison of actionable alterations in cancers with** 3 **kinase fusion, mutation, and amplification**

4

5 **Short title:** Kinase alterations in cancer

6

7 Shinsuke Suzuki^{1,2,3*}, Toshiaki Akahane^{1,4}, Akihide Tanimoto⁴, Michiyo Higashi⁴, Ikumi

8 Kitazono⁴, Mari Kirishima⁴, Masakazu Nishigaki⁵, Toshiro Ikeda⁶, Shuichi Kanemitsu⁷,

9 Junichi Nakazawa⁸, Erina Akahane¹, Hiroshi Nishihara⁹, Kimiharu Uozumi¹⁰, Makoto

10 Yoshimitsu³, Kenji Ishitsuka³, Shin-ichi Ueno^{1,2}

11

12

13 ¹Cancer Center, Kagoshima University Hospital, Kagoshima, Japan

14 ²Department of Clinical Oncology, Course of Advanced Therapeutics, Kagoshima University

15 Graduate School of Medical and Dental Sciences, Kagoshima, Japan

16 ³Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima,

17 Japan

18 ⁴Department of Pathology, Kagoshima University Graduate School of Medical and Dental

19 Sciences, Kagoshima, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 ⁵Department of Genetic Counseling, International University of Health and Welfare (IUHW),

21 Tokyo, Japan

22 ⁶Department of Genetic Counseling, Kagoshima University Hospital, Kagoshima, Japan

23 ⁷Department of Plastic Surgery, Sagara Hospital, Kagoshima, Japan

24 ⁸Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan

25 ⁹Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

26 ¹⁰Department of Medical Oncology, National Hospital Organization Kagoshima Medical

27 Center, Kagoshima, Japan

28

29 *Corresponding author:

30 E-mail: suzuki2@m.kufm.kagoshima-u.ac.jp (SS)

31 **Abstract**

32 Kinase-related gene fusion and point mutations play pivotal
33 roles as drivers in cancer, necessitating optimized targeted therapy against these alterations.
34 The efficacy of molecularly targeted therapeutics varies depending on the specific alteration,
35 with great success reported for such therapeutics in the treatment of cancer with kinase fusion
36 proteins. However, the involvement of actionable alterations in solid tumors, especially in
37 relation to kinase fusions, remains incompletely understood. This study aimed to compare the
38 number of actionable alterations in patients with tyrosine or serine/threonine kinase domain
39 fusions, mutations, and amplifications. We analyzed 613 patients with 40 solid cancer types
40 who visited our division between June 2020 and April 2024. To detect alterations involving
41 multiple-fusion calling, we performed comprehensive genomic sequencing using
42 FoundationOne[®] companion diagnostic (F1CDx) and FoundationOne[®] Liquid companion
43 diagnostic (F1LCDx). Patient characteristics and genomic profiles were analyzed to assess
44 the frequency and distribution of actionable alterations across different cancer types. Of the
45 613 patients, 44 had fusions involving kinases, transcriptional regulators, or tumor
46 suppressors. F1CDx and F1LCDx detected 13 with kinase-domain fusions. We identified 117
47 patients with kinase-domain mutations and 58 with kinase-domain amplifications. The
48 number of actionable alterations in patients with kinase-domain fusion, mutation, or
49 amplification (median [interquartile range; IQR]) was 2 (1–3), 5 (3–7), and 6 (4–8),

50 respectively. Patients with kinase fusion had significantly fewer actionable alterations than
51 those with kinase-domain mutations and amplifications. However, those cancers with fusion
52 involving tumor suppressors tended to have more actionable alterations (median [IQR]; 4 [2–
53 9]). Cancers with kinase fusions tended to exhibit fewer actionable alterations than those with
54 kinase mutations and amplifications. These findings underscore the importance of detecting
55 kinase alterations and indicate the pivotal role of kinase fusions are strong drivers of cancer
56 development, highlighting their potential as prime targets for molecular therapeutics.

57

58 Introduction

59 The ability to determine complete exon sequencing of relevant tumor driver, suppressor,
60 and resistance genes is paramount for optimizing personalized medicine. Comprehensive
61 genome sequencing (CGS) can serve as a valuable detection tool for actionable alterations,
62 which provide the biological basis of tumorigenesis. Kinase-related gene fusions, point
63 mutations, and amplifications play an important role as drivers in cancer, necessitating
64 optimized targeted therapy against these alterations. The FoundationOne® companion
65 diagnostic (F1CDx) and FoundationOne® Liquid companion diagnostic (F1LCDx) are tissue-
66 and blood-based broad companion diagnostics that have been approved by the Food and Drug
67 Administration and clinically and analytically validated for all solid tumors. In Japan, F1CDx
68 and F1LCDx are covered by public health insurance only after completion of standard
69 treatment, which differs from practices in other countries [1].

70 Gene fusion, particularly those involving tyrosine kinase, plays a pivotal role as a driver
71 mutation in the development of cancer. A hallmark example is the Philadelphia chromosome
72 9–22 translocation, characteristic of chronic myelogenous leukemia (CML), which generates
73 the fusion protein BCR–ABL1 [2,3]. CML, driven by the tyrosine kinase gene fusion *BCR–*
74 *ABL1*, stands out as the tumor with the most notable success in molecularly targeted
75 therapeutics to date. Remarkably, almost 11 years of follow-up have shown that the efficacy
76 of imatinib, a molecularly targeted drug, persists over time [4].

77 The prognosis of patients with non-small cell lung cancer (NSCLC) harboring
78 oncogenic driver-gene alterations, such as epidermal growth factor receptor (EGFR) kinase
79 mutation, anaplastic lymphoma kinase (ALK) fusion, c-ros oncogene 1 (ROS1) fusion, or
80 rearranged during transfection (RET) fusion, and those with pan-cancer harboring
81 neurotrophic tyrosine receptor kinase genes 1/2/3 (NTRK1/2/3) fusion, as well as those with
82 cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) fusion has
83 improved prominently with the advent of molecularly targeted drugs. However, the
84 therapeutic effects of tyrosine kinase inhibitors (TKIs) vary between EGFR mutation and
85 ALK, ROS1, RET, NTRK1/2/3 FGFR2 fusion. A tail-plateau, which is synonymous with
86 durable response on a Kaplan–Meier survival curve, represents an attractive effect of
87 molecularly targeted therapies [4] and immune checkpoint inhibitors [5,6] and has great
88 clinical significance. In patients with advanced NSCLC with EGFR-mutations, not only the
89 first generation of gefitinib but also the third generation of osimertinib, which is effective
90 against the resistance mutation EGFR T790M, limited the durability of the response and did
91 not show the benefit of tail-plateau on progression-free survival (PFS) curves [7,8]. However,
92 TKIs in NSCLC cases with ALK [9] [10], ROS1 [11], RET fusion [12] and in pan-cancer
93 with NTRK1/2/3 fusion [13] exhibited a tail plateau on the PFS curve. Further, Gao et al.
94 analyzed a cohort of 9,624 samples from The Cancer Genome Atlas with 33 cancer types to
95 detect gene fusion events. They focused on kinase fusion and showed that tumors with fusion

96 events tend to have a lower mutational burden [14].

97 In this study, we hypothesized that the smaller the number of actionable alterations, the
98 stronger the tumorigenesis and that the efficacy of targeted therapy would depend on the
99 driver kinase alterations. Therefore, we aimed to compare the number of actionable
100 alterations in patients with tyrosine or serine/threonine domain fusions, mutations, and
101 amplifications using tissue- and blood-based CGS.

102

103 **Materials and Methods**

104 **Patients**

105 In total, 613 patients with 44 different solid cancer types visited our division
106 between June 2020 and April 2024. Of these, 504 patients (82.2%) and 109 patients (17.8%)
107 were analyzed using tissue- and blood-based CGS, respectively. All patients had solid cancer
108 with advanced stage, with performance status of 0 or 1, and had completed standard treatment
109 covered by Japanese health insurance. This cohort also included patients with untreated rare
110 cancers and sarcomas lacking standard treatment protocols. We did not exclude any patients
111 tested by these assays during the data collection period, except patients who were analyzed
112 by F1LCDx and received anti-epidermal growth factor receptor (EGFR) antibody therapy.
113 This exception was due to blood-based sequencing identifying multiple novel mutations,
114 copy gains, and fusions associated with anti-EGFR therapy that frequently co-occur as

115 subclonal alterations in the same patient [15]. We are reporting a retrospective study of
116 medical records. The data were accessed for research purposes on 19 May 2024. We had
117 access to information that could identify individual participants during or after data
118 collection. These 40 cancer types were adenoid cystic carcinoma, bladder urothelial
119 carcinoma, brain low grade glioma, breast invasive carcinoma, cervical squamous cell
120 carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma,
121 esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma,
122 kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, lung
123 adenocarcinoma, lung squamous cell carcinoma, mesothelioma, neuroendocrine tumor, NUT
124 carcinoma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma,
125 pheochromocytoma and paraganglioma, porocarcinoma, prostate adenocarcinoma, sarcoma,
126 skin cutaneous melanoma, stomach adenocarcinoma, testicular germ cell tumor, thymoma,
127 thyroid carcinoma, uterine carcinosarcoma, uterine corpus endometrial carcinoma, and uveal
128 melanoma. Patient characteristics such as sex, age, smoking, heavy drinking (approximately
129 60g or more of pure alcohol per day average), prior chemotherapy, prior targeted therapy, and
130 F1CDx or F1LCDx analyses have all been postulated to affect the number of actionable
131 alterations (Table 1).

132

133 **Table 1. Baseline characteristics of different subgroups (n=197)**

	Kinase alteration			Fusion	p-value
Factor	Fusion	Mutation	Amplification	tumor suppressor	
n	13	117	58	9	
Female sex, no. (%)	5 (38.5)	64 (54.7)	25 (43.1)	2 (22.2)	0.14
Median age (SD)	56.46 (19.21)	61.22 (13.92)	59.34 (13.11)	67.78 (12.14)	0.245
Never smoked (%)	7 (53.8)	62 (53.0)	25 (43.1)	4 (44.4)	0.636
Heavy drinking (%)	1 (7.7)	17 (14.5)	10 (17.2)	2 (22.2)	0.768
Without prior chemotherapy (%)	8 (61.5)	75 (64.1)	43 (74.1)	7 (77.8)	0.489
Without prior targeted therapy (%)	12 (92.3)	104 (88.9)	55 (94.8)	9 (100.0)	0.448
blood-based CGS	3 (23.1)	13 (11.1)	4 (6.9)	2 (22.2)	0.192

(%)					
Median no. (IQR) of actionable alteration	2 (1- 3)	5 (3-7)	6 (4- 8)	4 (2- 9)	<0.001

134 CGS, comprehensive genome sequencing; IQR, interquartile range.

135

136 **Ethics approval**

137 This study was conducted in accordance with the Declaration of Helsinki and approved
138 by the Ethics Committee and Institutional Review Board of Kagoshima University (approval
139 number 180053). All patients provided written informed consent.

140

141 **Sequencing**

142 Next-generation sequencing was performed using F1CDx and F1LCDx, which are CGS
143 approaches involving the hybrid capture method. These tests targeted a panel of 324 genes,
144 identifying base substitutions, insertions, deletion mutations, and copy number alterations in
145 309 genes; gene fusion in 36 genes; and tumor mutational burden (TMB) (a measure of the
146 number of somatic protein-coding base substitutions and insertion/deletion mutations) in a
147 tumor specimen. Protein tyrosine kinase and serine/threonine kinase were analyzed for kinase
148 activating mutations. Amplification of CDK4/6, which coexists with other kinase alterations,

149 was excluded from kinase amplification in this study. SS18-SSX and NAB2-STAT6 are
150 disease-specific gene-fusion abnormalities and were detected separately via reverse-
151 transcription polymerase chain reaction.

152

153 **Actionable alterations**

154 All the detected gene alterations in cancer-related genes were annotated and curated
155 using the COSMIC (<https://cancer.sanger.ac.uk/cosmic>), ClinVar
156 (<https://www.ncbi.nlm.nih.gov/clinvar/>), CIViC (<https://civicdb.org/home>), SnpEff
157 (https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf), and Clinical
158 Knowledgebase (CKB) (<https://ckb.jax.org/>) databases. We calculated the validation
159 (database; score) for mutation or fusion and the validation (score) for amplification or the
160 clone status using PleSSision (Mitsubishi Space Software Co., Ltd., Tokyo, Japan), an
161 outsourcing clinical sequencing system [10]. Mutations with a total score of 2 points or more
162 were considered as actionable alterations. We used the following score tables:

163 i) for mutation or fusion of oncogenes: well-known driver status (more than 100 reports in
164 COSMIC or pathogenic in ClinVar; 2), gain of function (CKB; 2), likely gain of function
165 (CKB; 1.5), computational prediction of damage (SnpEff; 0.5);
166 ii) for mutation or fusion of tumor suppressor gene (TSG): germline loss of function (gLOF)
167 (pathogenic in ClinVar; 2), gLOF (truncate mutation; 2), gLOF (CKB or likely pathogenic in

168 ClinVar; 2), gLOF of computational prediction (SnpEff; 0.5), somatic loss of function
169 (sLOF) (pathogenic in ClinVar; 1), sLOF (truncate mutation; 1), sLOF (CKB or likely
170 pathogenic in ClinVar; 1), computational prediction of damage (SnpEff; 0.5);
171 iii) for amplification of an oncogene: neutral (0), copy number (CN)<4 (0), $CN \geq 4$ (1), $CN \geq 8$
172 (2),
173 iv) for deletion of TSG, neutral (0), loss of heterozygosity (LOH) (1), uniparental disomy
174 (UPD) (1), homologous deletion (HD) (2);
175 v) for clone status: main clone (1), subclone, tumor content >50% (1), subclone (0), uncertain
176 (0), not a cancer clone or inconsistent with pathology (0), not inherited by cancer clones (-
177 0.5).
178 For example, the TP53 R282W (LOH) mutation is annotated as sLOF (pathogenic in
179 ClinVar; 1), LOH (1), and main clone (1), with a cumulative score of 3. This would be
180 considered an actionable alteration, as our criteria specify that mutations with a cumulative
181 score ≥ 2 are actionable alterations.

182 A multidisciplinary team comprising medical oncologists, pathologists, clinical laboratory
183 technologists, bioinformaticians, and clinical geneticists conducted a comprehensive analysis
184 to ascertain the clinical significance of these gene alterations.

185

186 **Statistical analysis**

187 For number of actionable alterations, data are presented as median and interquartile
188 range. Statistical significance was determined using analysis of covariance and the Steel–
189 Dwass multiple comparison test. Results were considered significant at $P < 0.05$.

190

191 **Results**

192 **Detection of fusion-genes in kinases, transcriptional regulators,** 193 **and tumor suppressors**

194 We analyzed 613 patients with 40 solid-cancer types via CGS. Fig 1 presents the
195 distribution of patients with each cancer type. We identified 44 patients (9.6%) with fusions
196 involving kinases, transcriptional regulators, or tumor suppressors. F1CDx and F1LCDx
197 detected 13 patients (2.1%) with kinase-domain fusion (Table 2). In 12 of 13 patients with
198 kinase-domain fusion, except for patient 9 with *CDK6* amp (CN=98), the other kinase-
199 domain mutations and amplifications were mutually exclusive and did not coexist (Tables 1
200 and 3). Patient 13, with FGFR2-TACC2 fusion, exhibited coexistence with serine/threonine
201 kinase mutation, *MAP3K13 p.I523V*(LOH), which was categorized as a variant of unknown
202 significance. Additionally, patients 5, 6 and 11 showed coexistence of *MYC* amp (CN=9),
203 *KRAS p.Q61H*, and *MYC* amp (CN=11), respectively, which is an interpreted oncogene
204 (Table 3). Furthermore, all 13 patients demonstrated low TMB (Table 3).

205

206 **Fig 1. Proportions of cancer types in our sample.** We analyzed the data of 613 patients with
 207 40 different types of solid cancer using c tissue- and blood-based CGS.

208

209 **Table 2. Fusion detection in cancer (n=613)**

Cancer type	Type, No.	Fusion, 46 (7.5)		
	(%)	Kinase, 13 (2.1)	Transcriptional regulator, 24 (3.9)	Tumor suppressor, 9 (1.5)
Adenoid cystic carcinoma	-	-	<i>MYB-NFIB</i> , <i>MYB-AH11</i>	-
Breast invasive carcinoma	-	-	-	<i>PLAT-ETV6</i>
Cholangiocarcinoma	<i>TRIM4-MET</i> , <i>ANKRD55-</i> <i>FGFR1</i> <i>MYH9-ALK</i> <i>FGFR2-BICC1</i> (2)	<i>CALR-ZNF14</i>		<i>NF1-SSH2</i> , <i>TET2-UTRN</i> , <i>ATM-SLC35F2</i>
Colon adenocarcinoma	<i>SUPT3H-ROSI</i> ,	-		<i>NF1-TANC2</i>

Glioblastoma multiforme	<i>FGFR1-TACC1</i>	-	-
Kidney renal clear cell carcinoma	-	<i>Xp11-TFE3</i>	-
Low-grade glioma	<i>KIAA1549- BRAF</i>	<i>C11orf95-RELA, MNI-BEND2</i>	-
Neuroendocrine tumor	<i>SORCS1-RET</i>	<i>MLL-PHC2</i>	-
NUT carcinoma	-	<i>NUTM1-BRD4</i>	-
Pancreatic adenocarcinoma	<i>PPP1R9A-BRAF</i>	-	<i>TTC39B- CDKN2A</i>
Porocarcinoma	-	<i>NUTM1-BRD4</i>	-
Prostate adenocarcinoma	<i>SPINT1-IGF1R</i>	<i>TMPRSS2-ERG (5), ASXL1-STX16</i>	-
Sarcoma	-	<i>SS18-SSX*, TMPRSS2- ZNF317, ASPCR1-TFE3, MYOM1-STAT3, ATF1- EWSR1, EWSR1-FLI1(2), EWSR1-NR4A3, NAB2-</i>	-

		<i>STAT6*</i>	
Skin cutaneous Melanoma	<i>SUGTIP1-</i> <i>FGFR1</i>	-	<i>PTPN1-TMPO</i>
Stomach adenocarcinoma	<i>FGFR2-TACC2</i>	-	<i>CHI-CEBPA,</i> <i>POLE-ANKLE2</i>

210 Cancer types without fusions detected are not shown. Fusion genes detected multiple

211 times are indicated by numbers in parentheses.

212 *Disease-specific gene-fusion abnormalities were detected separately via reverse-

213 transcription polymerase chain reaction.

214

215 **Table 3. Actionable alterations of patients with kinase fusion (n=15)**

Patient	Cancer type	Kinase fusion	Actionable alterations (AA)	No. of AA	TMB (Muts/Mb)
1	cholangiocarcinoma	<i>TRIM4-</i> <i>MET</i>	-	0	1.26*
2	cholangiocarcinoma	<i>ANKRD55-</i> <i>FGFR1</i>	<i>IDH1 p.R132L, IKZF1</i> <i>p.R208*</i>	2	1.26
3	cholangiocarcinoma	<i>MYH9-</i>	<i>APC p.K139fs*30(LOH),</i>	2	2.41

		<i>ALK</i>	<i>GATA6 amp (CN=14)</i>		
4	cholangiocarcinoma	<i>FGFR2-</i> <i>BICC1</i>	<i>TSC1 p.S410*</i> , <i>BAP1</i> <i>p.E450fs*1</i>	2	0*
5	cholangiocarcinoma	<i>FGFR2-</i> <i>BICC1</i>	<i>MYC amp(CN=9)</i>	1	CBD
6	colon adenocarcinoma	<i>SUPT3H-</i> <i>ROS1</i>	<i>KRAS p.Q61H</i> , <i>APC</i> <i>p.E1379*(LOH)</i> , <i>TP53</i> <i>p.R282W(LOH)</i>	3	4
7	glioblastoma multiforme	<i>FGFR1-</i> <i>TACCI</i>	-	0	5
8	low grade glioma	<i>KIAA1549-</i> <i>BRAF</i>	-	0	0
9	neuroendocrine tumor	<i>SORCS1-</i> <i>RET</i>	<i>CDK6 amp(CN=98)</i>	1	3.79*
10	pancreatic adenocarcinoma	<i>PPP1R9A-</i> <i>BRAF</i>	<i>BAP1 p.Q261*</i>	1	3.79
11	prostate adenocarcinoma	<i>SPINT1-</i> <i>IGF1R</i>	<i>MYC amp(CN=11)</i> , <i>RBI</i> <i>HD</i> , <i>TP53</i> <i>p.K132E(LOH)</i>	3	1

12	skin cutaneous melanoma	<i>SUGTIP1-</i> <i>FGFR1</i>	<i>CDKN2A HD, CDKN2B</i> <i>HD, MTAP HD</i>	3	1.26
13	stomach adenocarcinoma	<i>FGFR2-</i> <i>TACC2</i>	<i>MAP3K13</i> <i>p.I523V(LOH), TP53</i> <i>p.C229fs*10</i>	2	1

216 TMB, tumor mutation burden; LOH, loss of heterozygosity; amp, amplification; CN,
217 copy number; HD, homozygous deletion; CBD, cannot be determined.

218 *Blood TMB analyzed using blood-based comprehensive genome sequencing.

219

220

221 We identified multiple complex chromosomal rearrangements involving *NUTM1*.

222 These included a possible translocation between *NUTM1* on chromosome 15q and a region

223 on chromosome 19p upstream of *BRD4* and a possible *BRD4-NUTM1* fusion in two patients

224 (one with NUT carcinoma and one with porocarcinoma) (Table 2). Whether this fusion

225 observed in porocarcinoma leads to the BRD4-NUTM1 fusion, which is characteristic of

226 NUT carcinoma, remains unknown.

227

228 **Cancers with kinase fusion tended to have fewer actionable**
229 **alterations**

230 We identified 117 patients (19.1%) with mutations and 58 patients (9.5%) with
231 amplifications involving the kinase domain (Table 1). After adjusting for baseline
232 characteristics (sex, age, smoking, heavy drinking, prior chemotherapy and prior targeted
233 therapy), we applied comprehensive genomic testing using F1CDx or F1LCDx to detect the
234 frequency of actionable alterations in patients with kinase-domain fusions (n=13), mutations
235 (117), amplifications (n=58), and suppressor fusion (n=9). The median counts (IQR) were 2
236 (1–3), 5 (3–7), 6 (4–8), and 4 (2–9), respectively ($P < 0.001$). The number of alterations was
237 significantly lower in patients with kinase fusion than in those with kinase-domain mutations
238 or amplifications ($P < 0.001$; Steel–Dwass multiple comparison test) (Fig 2). However, the
239 number of alterations was not statistically different for patients with suppressor fusions than
240 for those with kinase-domain mutations and amplifications (Fig 2). In addition, the cancers
241 with transcriptional-regulator fusion tended to have fewer actionable alterations **2 (0–3.5)**
242 (median [IQR]).

243

244 **Fig 2. Distribution of actionable alterations across each alteration group.** Patients with
245 kinase fusions had significantly fewer actionable alterations than patients with kinase
246 mutations and amplifications ($P < 0.001$; Steel–Dwass multiple comparison test). In contrast,
247 fusions involving tumor suppressors other than kinase fusion did not show a significant
248 difference in the number of actionable alterations.

249

250 **Discussion**

251 These findings reveal that 7.5% of the 613 patients exhibiting 40 types of solid cancer
252 patients included in the cohort had tumors with fusions. In particular, kinase fusions, which
253 may have particular structural properties that are selected for during oncogenesis, were
254 detected in 2.6% of the patients, accounting for 9 solid-cancer types. Cancers with kinase
255 fusions tended to have fewer actionable alterations than those with kinase mutations and
256 amplifications. Furthermore, the other kinase-domain mutations and amplifications were
257 generally mutually exclusive in most patients with kinase fusions. These findings suggest that
258 kinase fusion is a strong biological driver of cancer development. It is well established that
259 CGS of tumor DNA is less sensitive than other methods for detecting fusions. This is a
260 limitation of the study and requires further elaboration. Some tumors with fusions may have
261 been missed, and data from those cases may have been included in other cohorts (for
262 example, cases of kinase mutation only). Detection of fusion in DNA-sequencing data is
263 difficult, and bimodal DNA- and RNA-based gene panels can be useful for this detection.

264 The presence of *IGF1R-SPINT1* in prostate adenocarcinoma, which we detected in
265 patient 8, has not been previously reported. This fusion protein lacks an extracellular domain
266 but retains the kinase domain. Removing the entire extracellular domain of the insulin-like
267 growth factor (IGF) receptor activates the receptor, even without bound IGF [11]. Together

268 with previously reported findings, this result suggests that the *IGF1R-SPINT1* fusion
269 represents an activating mutation.

270 In patients 5, 6, 9, 11 and 13, we detected the coexistence of oncogene alterations with
271 kinase fusions, which are considered generally mutually exclusive (Table 3). The
272 amplification of *MYC* in patients 5 and 11 was limited to a small number of copies; CN=9
273 and CN=11, respectively. Furthermore, since the TSG (such as *RAD21* or *NBN*) in
274 chromosome 8q, where *MYC* is present, was amplified with a same copy number, it was
275 considered to be the result of polysomy of chromosome 8q. *KRAS p.Q61H* in patient 6 was
276 interpreted as a conflicting interpretation of pathogenicity in ClinVar. *MAP3K13* (encoding
277 LZK)-amplified head and neck squamous cell carcinoma cells harboring 3q gain are
278 dependent on LZK expression for cell viability and colony formation [16]. LZK expression
279 has been shown to be required for cell proliferation and anchorage- independent growth in
280 *MYC*-overexpressing breast and hepatocarcinoma cell lines [17]. However, alterations that
281 are predicted to inactivate LZK have also been reported in breast cancer [18]. Therefore, it is
282 unclear whether *MAP3K13 p.I523V*(LOH) in patient 13 functions as a tumor suppressor or an
283 oncogene. In these patients, the kinase fusions appear to be important for tumorigenesis even
284 with the coexistence of the oncogene alterations. Although there is only one co-existing
285 actionable alteration, high amplification of *CDK6* (CN=98) was detected in patient 9.
286 Sitthideatphaiboon et al. defined the pathways limiting EGFR-inhibitor response, including

287 cell-cycle-gene, *CDK4/6* amplification [19]. In such patients, the effect of TKIs is expected to
288 be influenced not only by the number but also by the type of comorbid actionable alterations.

289 Molecularly targeted drugs have been most successful in treating CML, which is driven
290 by a kinase fusion (*BCR-ABL1*) [4]. Integrative genomic analysis revealed cancer-associated
291 mutations in only three out of 19 patients (16%) who responded optimally to imatinib,
292 whereas cancer-gene variants were detected in 15 of 27 patients (56%) with poor outcomes
293 [20]. In our study, sole kinase fusion, without other actionable alterations, may be involved as
294 a significant driver of the development of cancer in three patients (with cholangiocarcinoma,
295 glioblastoma multiforme, and brain low grade glioma). However, in three patients with lung
296 adenocarcinoma harboring an activating EGFR kinase mutation (EGFR p.E746_A750del,
297 p.S768I, and p.L858R) without prior EGFR-targeted therapies, we detected 10, 4 and 3
298 actionable alterations, respectively. Moreover, all three patients had *TP53* loss-of-function
299 mutations in uniparental disomy (data not shown). *TP53* mutations associate with faster
300 resistance evolution in EGFR-mutant NSCLC and mediate acquisition of resistance mutations
301 to EGFR TKIs [21]. Therefore, it is important to validate tumor alterations, including both
302 driver and actionable mutations by CGS, to evaluate the efficacy of molecularly targeted
303 therapy.

304 Focusing on kinase fusion, Gao et al. [14] showed that a significant proportion of
305 patients harboring fusions involving cancer-driver genes had no driver-gene mutations.

306 Moreover, their analysis highlights an important consideration for immunotherapy in patients
307 with fusions. Specifically, the significantly lower mutational burden observed in patients with
308 driver-gene fusions points toward a reduced efficacy of immunotherapy in these patients,
309 despite fusion peptides being potentially good immunogenic targets. The TMB was also low
310 in all the 13 patients with kinase-domain fusion. Based on their findings, Gao et al. [14]
311 suggested that research into driver-gene fusion can result in the development of targeted
312 drugs and immunotherapy.

313 This study has a limitation in terms of the small sample size. We only included 13
314 patients with kinase-fusion in the analysis; therefore, it is unlikely that the analysis was
315 sufficiently powered to derive conclusions. Therefore, analysis of a large number of patients
316 may be necessary.

317

318 **Conclusions**

319 This study demonstrated that cancers with kinase fusion tend to have fewer actionable
320 alterations than those with kinase mutations and amplifications, reflecting the strong
321 dependence of tumorigenesis on kinase fusion. Therefore, detecting kinase mutations is
322 crucial in developing molecularly targeted therapeutics and immune therapy.

323

324

325 **Acknowledgments**

326

327

328

329 **References**

330 1. Aoyagi Y, Kano Y, Tohyama K, Matsudera S, Kumaki Y, Takahashi K, et al. Clinical
331 utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. PLOS ONE.
332 2022;17: e0266112. doi: 10.1371/journal.pone.0266112.

333 2. Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18: 930-
334 937. doi: 10.1158/1078-0432.CCR-10-1613.

335 3. Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid
336 leukaemia stem cells. Br J Pharmacol. 2013;169: 1693-1707. doi: 10.1111/bph.12183.

337 4. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-
338 term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:
339 917-927. doi: 10.1056/NEJMoa1609324.

340 5. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al.
341 Nivolumab versus docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N
342 Engl J Med. 2015;373: 123-135. doi: 10.1056/NEJMoa1504627.

343 6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-

- 344 year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.*
345 2019;381: 1535-1546. doi: 10.1056/NEJMoa1910836.
- 346 7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib
347 or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med.* 2010;362:
348 2380-2388. doi: 10.1056/NEJMoa0909530.
- 349 8. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH,
350 et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J*
351 *Med.* 2018;378: 113-125. doi: 10.1056/NEJMoa1713137.
- 352 9. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line
353 crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med.* 2014;371: 2167-
354 2177. doi: 10.1056/NEJMoa1408440.
- 355 10. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus
356 crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med.* 2017;377:
357 829-838. doi: 10.1056/NEJMoa1704795.
- 358 11. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al.
359 Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. *N Engl J Med.* 2024;390:
360 118-131. doi: 10.1056/NEJMoa2302299.
- 361 12. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy
362 of selpercatinib in RET fusion-positive non-small-cell lung cancer. *N Engl J Med.* 2020;383:

363 813-824. doi: 10.1056/NEJMoa2005653.

364 13. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib
365 in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated
366 analysis of three phase 1-2 trials. *Lancet Oncol.* 2020;21: 271-282. doi: 10.1016/S1470-
367 2045(19)30691-6.

368 14. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al. Driver
369 fusions and their implications in the development and treatment of human cancers. *Cell Rep.*
370 2018;23: 227–238.e3. doi: 10.1016/j.celrep.2018.03.050.

371 15. Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, et al.
372 Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal
373 growth factor receptor therapy in metastatic colorectal cancer. *J Clin Oncol.* 2023;41: 485-496.
374 doi: 10.1200/JCO.22.00364.

375 16. Edwards ZC, Trotter EW, Torres-Ayuso P, Chapman P, Wood HM, Nyswaner K, et
376 al. Survival of head and neck cancer cells relies upon LZK kinase-mediated stabilization of
377 mutant p53. *Cancer Res.* 2017;77: 4961-4972. doi: 10.1158/0008-5472.CAN-17-0267.

378 17. Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, et al. The MAP3K13-TRIM25-
379 FBXW7alpha axis affects c-Myc protein stability and tumor development. *Cell Death Differ.*
380 2020;27: 420-433. doi: 10.1038/s41418-019-0363-0.

381 18. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The

382 landscape of cancer genes and mutational processes in breast cancer. *Nature*. 2012;486: 400-
383 404. doi: 10.1038/nature11017.

384 19. Sitthideatphaiboon P, Teerapakpinyo C, Korphaisarn K, Leelayuwatanakul N,
385 Pornpatrananrak N, Pongvarin N, et al. Co-occurrence CDK4/6 amplification serves as
386 biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung
387 cancer. *Sci Rep*. 2022;12: 2167. doi: 10.1038/s41598-022-06239-y.

388 20. Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative
389 genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with
390 high-risk disease. *Blood*. 2018;132: 948-961. doi: 10.1182/blood-2018-02-832253.

391 21. Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, et al. Concurrent
392 TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. *J Thorac*
393 *Oncol*. 2022;17: 779-792. doi: 10.1016/j.jtho.2022.02.011.

394

395 **Financial Disclosure Statement**

396 This work was supported by a JSPS KAKENHI grant (grant number 19K08870 to S.S.) for
397 Clinical Research (Grant-in-Aid for Scientific Research) from the Ministry of Education,
398 Culture, Sports, Science and Technology of Japan. We thank Mr. Sachio Nohara for his
399 helpful suggestions.

400 **Authors' contributions**

401 SS designed and performed the experiments, analyzed the data, and wrote and revised the
402 manuscript. TA and EA conducted the experiments. AT, MH, IK, MK, MN, TI, SK, JN, HN,
403 KU, MY, KI, and SU analyzed the data and wrote and revised the manuscript.

404 **Data Availability Statement**

405 The data that support the findings of this study are available on request from the
406 corresponding author, S.S. The data are not publicly available as the study participants did
407 not consent to public sharing of their data.


408 **Competing interests**

409 The authors declare no competing interests.

410

411

medRxiv preprint doi: <https://doi.org/10.1101/2024.05.24.24307888>; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Figure

medRxiv preprint doi: <https://doi.org/10.1101/2024.05.24.24307868>; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

